Update on tolterodine extended-release for treatment of overactive bladder
نویسندگان
چکیده
Overactive bladder is a prevalent condition which negatively impacts quality of life and puts a significant economical burden on society. First-line therapy often includes pharmacotherapy with antimuscarinic medications, and numerous research studies have demonstrated that tolterodine extended-release (ER) is an efficacious and tolerable formulation of this class of medication. This review provides an update on the clinical use of tolterodine ER, detailing the current literature on its efficacy, tolerability, adverse effects, and comparability with other commonly prescribed medications for the treatment of overactive bladder.
منابع مشابه
Treatment of Overactive Bladder Symptoms with Extended Release Fesoterodine Fumarate
Fesoterodine extended-release (brand name Toviaz) is a new competitive muscarinic receptor antagonist labeled for the treatment of overactive bladder (OAB). Here we have undertaken a substantial update to a systematic review evaluating the effects of fesoterodine in the treatment of OAB. Our results indicate that fesoterodine was found to have significant improvements in the management of OAB s...
متن کاملUse of Tolterodine extended Release in Overactive Bladder
Overactive bladder (OAB) is a common problem whose prevalence increases with advancing age and compromises health-relatedqualityoflife.TolterodinewasthefirstantimuscarinicdrugspecificallydesignedtotreatOAB. ThroughMEDLINE,wereviewedarticles,standardizationreportsandmeetingabstracts,publishedbetween2001and2011,ontheefficacy and tolerability of Tolterodine extended...
متن کاملThe safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
After lifestyle and behavioral measures to control overactive bladder, the mainstay of pharmacological treatment is the use of antimuscarinic therapy. Overactive bladder predominantly affects older people, who experience the most severe disease, and are also at a greater risk of side effects from antimuscarinic therapy. Thus it is imperative that data are available on the efficacy and tolerabil...
متن کاملA pharmacoeconomic model comparing two long-acting treatments for overactive bladder.
OBJECTIVE To compare the estimated first-line treatment costs of extended-release tolterodine versus controlled-release oxybutynin in patients with overactive bladder (OAB). METHODS We developed a decision-analysis model to estimate the patterns of treatment, resource consumption, and cost impact of treating OAB with either controlled-release oxybutynin or extended-release tolterodine as firs...
متن کاملPrk8 Health Related Quality of Life (hrqol) in Chronic Dialysis Patients:a Critical Comparison of Continuous Ambulatory Peritoneal Dialysis (capd) and Centre Hemodialysis (chd)
OBJECTIVES: To compare the estimated first-line treatment costs of extended-release tolterodine versus controlled-release oxybutynin in patients with overactive bladder patients (OAB). METHODS: Data from a randomized clinical trial (Curr Med Res Opin 2002; 18:177–184), showing greater improvement in bladder condition for patients taking extended-release tolterodine compared to controlled-releas...
متن کامل